Watching MIRA Pharmaceuticals; Zacks Small-Cap Research Says Co Is Creating A THC Analog That Has The Same Benefits As THC Without The Negative Side Effects. We Value MIRA At $16.50 Using Discontinued Cash Flow Analysts And A 20% Discount Rate
关注MIRA Pharmaceuticals;Zacks Small-Cap Research表示,该公司正在开发一种与四氢大麻酚具有相同益处且没有负面副作用的四氢大麻酚类似物。使用已停产的现金流分析师和20%的折扣率,我们将MIRA估值为16.50美元